Introduction
It is commonly believed that exposure to medications during pregnancy can be harmful to the unborn child. Women requiring drug treatment for chronic diseases are often concerned and, consequently, seek information from family, friends, and health care providers to assist them in this decision-making process. It is crucial that women receive balanced, evidence-based information concerning drug exposures during pregnancy. 1, 2 Unfortunately, health care professionals do not always disseminate evidence-based information. Results from an international survey recorded that a relatively small proportion of community pharmacists provided evidence-based information regarding the drugs in question. Only 14% referred to current medical literature, while 60% consulted the product monograph (which does not include evidence-based pregnancy data). More than 90% of pharmacists referred the client to their physician. 3 Family physicians are usually the first health care professional that women see to confirm a diagnosis of pregnancy. A study conducted in Canada and Australia evaluated family physicians' attitudes and practices surrounding the use of antidepressants in pregnancy. The study found that physicians from both countries felt strongly that advice regarding antidepressant use during pregnancy was a difficult task, and most did not feel comfortable giving information. 4 Health care professionals are generally more supportive than family and friends about taking medications during pregnancy. However, negative information given by a health care provider is generally more upsetting, because these individuals are trusted to provide evidence-based information. After receiving negative information from a health care provider, especially a physician, it is difficult for women to accept that reassuring evidence-based information is accurate. Consequently, despite such evidence-based reassurance, women who continue using the medication remain worried and feel guilty because they cannot forget the initial negative information they received. 5 This can be particularly critical in relation to psychiatric medications. Another study was conducted to determine perception of the risk of antidepressant drugs by pregnant women with depression and the efficacy of evidence-based counseling. Women who called The Motherisk Program requesting information about the safety of an antidepressant during pregnancy were compared with two other groups: 1) women who called about antibiotic use (i.e., non-teratogenic drugs used short-term); and 2) women who called about gastric medications (i.e., non-teratogenic drugs used long-term). Their perception of risk was measured before and after evidenced-based information was given. Despite receiving evidence-based reassuring information, 15% of antidepressant users, compared to 4% using gastric drugs and 1% using antibiotics, chose to discontinue their medication. 1 There are few studies in the peer-reviewed literature documenting physicians' attitudes and practices regarding the use of psychotropic drugs in pregnancy, and none from Latin America. The objective of this study was to evaluate risk perception of psychotropic use during pregnancy among different medical specialties.
This study followed the standards required by the Helsinki Declaration and was approved by the Research Ethics Committee of Universidade Federal de Pernambuco (protocol no. 305).
Methods
This was a convenience survey that was conducted at outpatient clinics in cities in Brazil (Recife) and Argentina (Buenos Aires, La Plata, and Bahía Blanca). Each physician was personally approached and asked to complete a questionnaire after signing a consent form.
Information such as age, sex, and date of graduation was collected. Participants were asked to rate their perception of teratogenic risk regarding different drug classes between two options: each particular drug may cause malformations between 1-5%, or higher than 5%. The following drug classes were evaluated: antidepressants, antipsychotics, anticonvulsants, and benzodiazepines. A specific item (whether the respondent considers that psychotropic medications may be more harmful to the fetus than other medications) was included as the last question. To verify physicians' degree of interest in this topic, they were also asked whether they had read anything, either in the lay press or the scientific literature, or if they had attended a lecture or taken a course on this topic.
The responses of different medical specialists were compared. Statistical analyses consisted of the chi-square or Fisher's exact test for categorical data and the KruskalWallis test for continuous data. Differences were considered significant when p , 0.05.
Results
A total of 238 surveys from medical professionals, 120 from Brazil and 118 from Argentina, were analyzed. The sample consisted of medical specialists in psychiatry, obstetrics, neurology, cardiology, gastroenterology, and family medicine. Each medical specialty was represented by 40 participants (except for gastroenterologists, n=38), 20 from each country. The mean age of the sample was 37 years, and the gender distribution was similar (116 women and 121 men, 48.9 and 51.1% respectively); mean time since graduation was 12 years. The median age and gender distribution did not show differences among specialties. Family physicians were the more recent graduates (Table 1) .
Perception of higher teratogenic risk (malformations in more than 5% of cases when used during pregnancy) was reported by most of the sample (82.7%) regarding anticonvulsants, followed by antipsychotics (60.9%), benzodiazepines (52.8%), and antidepressants (49.2%).
For anticonvulsants, a perception of higher teratogenic risk (malformations in more than 5% of cases when used during pregnancy) was reported by 82.7% of the sample, vs. 60.9% for antipsychotics, 52.8% for benzodiazepines, and 49.2% for antidepressants.
Among different specialties, there were differences in risk perception regarding antidepressants, antipsychotics, and benzodiazepines, but not anticonvulsants. Psychiatrists perceived the least risk regarding these drug classes, compared with other specialists (Table 2) .
For the specific question at the end of the questionnaire, 42.6% (101 of 237) of the sample considered that psychiatric medications during pregnancy were potentially more harmful than other drug classes (Table 3) .
Among specialties, only 7 of 40 (17.5%; p = 0.004) psychiatrists considered psychotropics to be more harmful. Excluding this group, there were no statistical differences in risk perception among the other specialists (p = 0.334), but cardiologists and family physicians tended to perceive a higher risk regarding psychotropics compared with other medications. Following psychiatrists, neurologists were the specialists that most often prescribed psychotropics (95%), whereas obstetricians prescribed them least (35%).
Regarding questions about interest in the subject, more respondents answered having read some scientific 
Discussion
To our knowledge, this is the first survey of its kind to be conducted in Latin America (specifically, Brazil and Argentina), and the results appear to be similar to those of surveys conducted in North America and Europe. This suggests that fear surrounding the use of psychotropic drugs in pregnancy is a worldwide phenomenon. This is a concern, because mental illness is prevalent worldwide and, to date, few guidelines are available for treatment of pregnant women diagnosed with a psychiatric disorder. We could find only two guidelines specifically designed for pregnant women with depression and other psychiatric disorders, published by the UK National Institute for Clinical Excellence (NICE) 6 and by the American Psychiatric Association. 7 However, these guidelines are very conservative regarding the use of psychotropic drugs in pregnancy, and are intended primarily for women who are planning to become pregnant. As almost half of all pregnancies are unintended, 8 many women approach their health care providers when they are already pregnant and taking a medication, requesting information regarding drug safety.
In our survey, 42.6% of the sample thought that psychotropics during pregnancy were more harmful than other drug classes. Anticonvulsants as a group were perceived to cause malformations in more than 5% of cases by the majority of the sample, which was consistent with each specialty and with the evidence-based literature. 9 Antipsychotics were considered potentially more harmful by more than 60% of the sample, mostly by nonpsychiatrists, perhaps because there is less information about risk and safety, although antipsychotics have not been definitively associated with a higher risk of birth defects. 10 Benzodiazepines were considered more harmful by 52.8% of the sample, although available information regarding potential teratogenic risk considers them relatively safe for use in pregnancy. In a recent updated meta-analysis, 11 the overall risk of malformations associated with benzodiazepines from cohort studies was 1.07 (95% confidence interval 0.91-1.25). However, a former finding of increased risk of oral clefts detected in casecontrol studies 12 could not be reassessed, as there were no new studies addressing this specific malformation.
Antidepressants were considered to have less teratogenic potential, as less than half of the participants believed them to cause malformations in more than 5% of cases. This is consistent with available evidence-based information regarding the safety of these drugs, as antidepressants do not appear to pose a major teratogenic risk. 13 Currently, other medical specialties (especially family physicians) are more often called upon to prescribe antidepressants in pregnancy. This is likely for a number of reasons, including a higher prevalence of depression in the population, shortage of psychiatrists in many geographic regions, and more reassuring information regarding the safety of antidepressants in pregnancy compared with other psychotropic drugs.
Most of the sample, including psychiatrists (98.3%), perceived that chemotherapeutics are more harmful when administered to pregnant women, followed by anticonvulsants (82.7%). Other medications, such as antibiotics, antihypertensives, corticosteroids, and gastric medications, were considered harmful by 38.6, 29.8, 20.4, and 9.9% of the sample, respectively. In addition, the other specialists were specifically asked if they were comfortable with prescribing medications other than psychotropics during pregnancy, and 110 (46.2%) physicians answered that they were. We therefore interpreted this response to mean that the overestimated risk related with the prescribing of psychotropics by other specialties was not due to a general cautiousness towards prescribing medications during pregnancy.
Most psychiatrists considered that, excluding antiepileptics, psychotropic agents (antipsychotics, benzodiazepines, and antidepressants) did not pose a . 5% risk of producing birth defects. Other specialists tended to overestimate the teratogenic risk associated with these drug classes. This may be explained by the fact that psychiatrists are more likely to treat a pregnant woman requiring psychotropic drugs and consult the scientific literature more frequently.
The limitations of this study include a small sample size and the possible selection bias inherent to a convenience sample. In addition, this was not a randomized sample of physicians in each country; therefore, findings cannot necessarily be generalized. Some of the respondents were casually known to the authors in their respective medical communities, and this was likely responsible for the high response rate. However, it is unlikely to have had an effect on their responses to the questionnaire.
In summary, in this sample of physicians from Brazil and Argentina, the perception of risk associated with the use of psychotropic drugs in pregnancy was overestimated by non-psychiatric specialists, while psychiatrists reported a perception of risk consistent with evidencebased information.
Therefore, increased training (lectures, courses, etc.) on the use of psychotropic drugs in pregnancy is recommended among non-psychiatric specialists, as they also care for pregnant women taking these medications.
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